acetylcysteine 200 MG/ML Inhalation Solution

What the CMS Formulary Data Shows for acetylcysteine 200 MG/ML Inhalation Solution

Per the CMS 2026 Part D formulary file, acetylcysteine 200 MG/ML Inhalation Solution (RxNorm concept RXCUI 307719, generic name acetylcysteine) appears on 309 distinct formulary files spanning 4,944 Medicare Part D plan offerings - 97.6% of enrollable Part D products, near-universal placement. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.4.

Real-world access to acetylcysteine 200 MG/ML Inhalation Solution depends on utilization management as much as tier placement: 99.7% of covering formularies require prior authorization. 0% require step therapy. 0.6% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 4,830 Part D beneficiaries filled acetylcysteine 200 MG/ML Inhalation Solution in 2023, with total plan-and-beneficiary spending of $1,834,431 and an average per-beneficiary annual cost of $379.80. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry acetylcysteine 200 MG/ML Inhalation Solution today.